Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Net Margin of 5555.34% in Q4 2024, up 131.79% quarter-over-quarter from 17476.92% in Q3 2024, and up 555179.0% on a YoY basis from N/an in Q1 2024.
Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' Net Margin history runs 4 years deep, the most recent figure standing at 5555.34% for Q4 2024.
- In Q4 2024, Net Margin rose 555179.0% year-over-year to 5555.34%; the TTM figure through Sep 2025 stood at 22357.74% (up 2251523.0% YoY), while the FY2024 annual figure was 344.67%, down 35707.0% from the prior year.
- Net Margin was 5555.34% for Q4 2024 at Amylyx Pharmaceuticals, up from 17476.92% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 5555.34% in Q4 2024 to a low of 17476.92% in Q3 2024.
- Historically, Net Margin has averaged 3387.31% across 4 years, with a median of 134.01% in 2024.
- The sharpest annual moves came in 2023 and 2024: Net Margin soared 984777 bps in 2023, then plunged 1749727 bps in 2024.
- A 4-year view of Net Margin shows it stood at 8120.0% in 2021, then surged by 98 bps to 196.95% in 2022, then surged by 102 bps to 3.55% in 2023, then jumped by 156372 bps to 5555.34% in 2024.
- The last three Net Margin figures came in at 5555.34% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 9.19% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 26.57% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 35.18% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 2.94% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 24.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 4.16% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -168.42% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.15% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 31.38% |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,555.34% |
| Sep 30, 2024 | -17,476.92% |
| Jun 30, 2024 | -7,106.55% |
| Mar 31, 2024 | -134.01% |
| Dec 31, 2023 | 3.55% |
| Sep 30, 2023 | 20.35% |
| Jun 30, 2023 | 20.36% |
| Mar 31, 2023 | 1.86% |
| Dec 31, 2022 | -196.95% |
| Sep 30, 2022 | -9,827.42% |
| Sep 30, 2021 | -8,120.00% |